ABX4233

ABX4233: sourced facts only. name: "We identified a lead candidate, ABX4233, that simultaneously engages LTBR and B7-H4, without blocking LTBR binding to LTαββ or LIGHT, and exhibits B7-H4-dependent LTBR agonism with sub-nanomolar potency." [DOI:10.1158/1538-7445.am2025-lb230]; target: "We identified a lead candidate, ABX4233, that simultaneously engages LTBR and B7-H4, without blocking LTBR binding to LTαββ or LIGHT, and exhibits B7-H4-dependent LTBR agonism with sub-nanomolar potency." [DOI:10.1158/1538-7445.am2025-lb230]; target: "We identified a lead candidate, ABX4233, that simultaneously engages LTBR and B7-H4, without blocking LTBR binding to LTαββ or LIGHT, and exhibits B7-H4-dependent LTBR agonism with sub-nanomolar potency." [DOI:10.1158/1538-7445.am2025-lb230]; developer: "NGM Biopharmaceuticals, Inc., South San Francisco, CA." [DOI:10.1158/1538-7445.am2025-lb230]; modality: "To this end, we generated bispecific antibodies that targeted both LTBR and B7-H4 and screened them for B7-H4-dependent LTBR agonism." [DOI:10.1158/1538-7445.am2025-lb230]; stage: "In vivo, ABX4233 evoked dose- and B7-H4-dependent LTBR agonism in a homotypic xenograft tumor model." [DOI:10.1158/1538-7445.am2025-lb230]